Hester Biosciences Ltd.
Snapshot View

2174.60 +5.05 ▲0.2%

27 May 2022, 04:01:00 PM
Volume: 200

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.hester.in
Market Cap 1,866.32 Cr.
Enterprise Value(EV) 2,047.27 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 46.22 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 47.05 Trailing Twelve Months Ending 2022-03
Industry PE 28.15 Trailing Twelve Months Ending 2022-03
Book Value / Share 305.62 Trailing Twelve Months Ending 2022-03
Price to Book Value 7.12 Calculated using Price: 2,174.60
Dividend Yield 0.46 Period Ending 2021-03
No. of Shares Subscribed 0.85 Cr. 8,506,865 Shares
FaceValue 10
Company Profile

Hester Biosciences was incorporated on April 29, 1987 as a Private Limited Company by the name of Hester Pharmaceuticals Limited. It was subsequently converted into a Public Limited Company on November 1, 1993. The company is engaged in the manufacturing of poultry vaccines. The company has been promoted by Rajiv D. Gandhi his brother Sanjiv D. Gandhi and Dr. Bhupendra V. Gandhi. The company changed its name to the present in 2008.

The company is a 100% biotech company producing animal biologicals. Located near the city of Ahmedabad, in the state of Gujarat, in Western India, Hester has a state-of-the-art facility to produce live and killed (Inactivated) veterinary vaccines.

Production procedures for poultry vaccines based on in-house advanced capabilities are being followed in the areas of virus propagation in specific pathogen-free embryos, tissue culture, batch fermentation of bacteria, lyophilisation and emulsion preparation.

Hester on December 22, 2008 launched a poultry vaccine against Coryza disease in chicken, containing 3 serotypes – A, B & C.

Hester is the first company in India to manufacture the Coryza vaccine with 3 strains as against other companies manufacturing the vaccine with only 2 serotypes - A & C. Coryza disease is of economical importance to poultry farmers as it causes a drop in egg production in laying birds.

Hester currently manufactures 39 types of poultry vaccines against various poultry diseases.

Product range of the company includes:

  • Live Vaccines
  • Killed Vaccines
  • Diagnostic kits &  Seromonitoring services

Achievements/ recognition:

  • GMP and ISO 9001:2000 certified company

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.23%
1 Week
-4.50%
1 Month
-16.85%
3 Month
-1.99%
6 Month
-4.66%
1 Year
-19.98%
2 Year
+91.17%
5 Year
+157.06%
10 Year
+2410.22%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 14.28 12.88 16.73 20.56 20.38 17.57 25.59 16.38 16.16
Return on Capital Employed (%) 20.10 17.78 17.26 18.98 19.75 20.20 26.64 16.53 17.33
Return on Assets (%) 8.28 6.89 8.84 11.08 11.43 10.10 14.97 9.04 8.70

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 67 75 85 102 122 141 177 201 228 260
Non Curr. Liab. 16 20 38 41 48 44 70 97 114 198
Curr. Liab. 39 45 35 38 38 55 49 83 61 97
Minority Int. 1 1 3 5 5 4 4 5 8 7
Equity & Liab. 124 142 160 186 213 244 299 387 411 562
Non Curr. Assets 74 85 100 112 133 146 158 227 250 367
Curr. Assets 50 57 60 74 80 98 142 159 162 195
Misc. Exp. not W/O
Total Assets 124 142 160 186 213 244 299 387 411 562

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 65 69 90 101 123 136 178 183 214 235
Other Income 0 1 0 1 0 3 7 6 5 14
Total Income 65 70 90 102 124 138 185 190 219 249
Total Expenditure -43 -45 -65 -68 -82 -89 -110 -128 -146 -175
PBIDT 22 25 26 34 41 50 75 62 73 74
Interest -3 -6 -5 -4 -4 -4 -7 -7 -7 -4
Depreciation -4 -5 -6 -6 -7 -10 -12 -13 -13 -17
Taxation -5 -4 -5 -6 -8 -13 -16 -10 -15 -14
Exceptional Items 3 -3
PAT 9 9 13 19 23 23 41 31 35 39
Minority Interest 0 0 0 0 1 3 1 -2 0 0
Share Associate 0
Other Related Items
Consolidated Net Profit 9 9 14 19 24 26 42 29 34 39
Adjusted EPS 11 11 16 23 28 30 49 34 40 46

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 14 12 9 20 19 35 38 47 37 58
Cash Fr. Inv. -10 -23 -15 -21 -13 -30 -26 -22 -74 -38
Cash Fr. Finan. -2 10 7 7 -7 2 -11 3 19 -18
Net Change 2 -1 2 5 -1 6 1 28 -19 1
Cash & Cash Eqvt 3 2 4 6 5 11 12 41 24 21

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 53.73 53.73 53.73 53.73 53.73 53.73 53.73 53.73 53.73
Public 46.27 46.27 46.27 46.27 46.27 46.27 46.27 46.27 46.27
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 26 May 2022
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Submission of earnings conference call held on Friday 20 May 2022 to discuss the standalone and consolidated audited financial results for the quarter and year ended 31 March 2022.
Mon, 23 May 2022
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) this is to inform you that we are in receipt of intimation from the shareholder regarding loss of share certificate(s).
Mon, 23 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report of the Company for the year ended 31 March 2022

Technical Scans View Details

Fri, 27 May 2022
Closing Above Previous High Closing Above Previous High
Making Lower Lows for 3 days Making Lower Lows for 3 days
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease 1 Month High Decrease 1 Month
High Increase 2 Years High Increase 2 Years

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 216,539.98 902.50 +0.2%
Divi's Laboratories Ltd. 93,297.61 3,514.45 +1.9%
Cipla Ltd. 77,954.36 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. 73,094.23 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. 55,313.96 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. 49,744.83 2,939.85 +1.3%
Gland Pharma Ltd. 47,677.82 2,897.00 +1.5%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 33.60 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2022-03 31.51 3,514.45 +1.9%
Cipla Ltd. Consolidated 2022-03 30.97 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 33.49 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 52.40 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 64.02 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2022-03 39.35 2,897.00 +1.5%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.19 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2022-03 7.95 3,514.45 +1.9%
Cipla Ltd. Consolidated 2022-03 3.74 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.80 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 9.81 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8.36 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2022-03 6.66 2,897.00 +1.5%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 0.10 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,897.00 +1.5%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 14.13 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,897.00 +1.5%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 14.13 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,897.00 +1.5%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 19,159.59 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,897.00 +1.5%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 902.50 +0.2%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,514.45 +1.9%
Cipla Ltd. Consolidated 2021-03 2,401.30 966.15 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,392.00 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,847.00 +4.9%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,939.85 +1.3%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,897.00 +1.5%